Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with CT‐P13 biosimilar 5 mg/kg (low certainty).
Infliximab 5 mg/kg and purine analogues probably leads to higher clinical remission as defined by the studies at weeks 24–26 compared with purine analogues alone (moderate certainty).
Infliximab 5 mg/kg and purine analogues probably leads to higher clinical response as defined by the studies at week 26 compared with purine analogues alone (moderate certainty).
Infliximab 5 mg/kg and purine analogues showed no clear difference in withdrawals due to adverse events at week 26 compared with purine analogues alone (low certainty).
Tofacitinib leads to lower failure to achieve clinical remission (5 mg/10 mg) compared with placebo (high certainty).
Tofacitinib leads to lower failure to maintain clinical response (5 mg/10 mg) compared with placebo (high certainty).
Tofacitinib leads to lower failure to achieve endoscopic remission (5 mg/10 mg) compared with placebo (high certainty).
Tofacitinib showed no clear difference in adverse events (5 mg/10 mg) compared with placebo (high certainty).
Tofacitinib showed no clear difference in serious adverse events (5 mg/10 mg) compared with placebo (low certainty).
Tofacitinib probably leads to lower withdrawals due to adverse events (5 mg/10 mg) compared with placebo (moderate certainty).
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in failure to induce clinical remission at week 10 compared with placebo and two infusions of infliximab (moderate certainty).
The review found no eligible studies for this question.
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in adverse events up to week 10 compared with placebo and two infusions of infliximab (moderate certainty).
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in withdrawal due to adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).
Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in serious adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).
It is very uncertain whether other prokinetics changes not symptom‐free or no symptoms improvement (itopride 50 three times… compared with domperidone 10mg three times a day (very low certainty).
It is very uncertain whether cannabis cigarettes (115 mg THC) changes proportion of patients achieving clinical remission compared with placebo cigarettes (very low certainty).
It is very uncertain whether cannabis cigarettes (115 mg THC) changes proportion of patients achieving clinical response compared with placebo cigarettes (very low certainty).
Cannabis cigarettes (115 mg THC) showed no clear difference in CRP (mg/dL) at end of study compared with placebo cigarettes (low certainty).
The review found no eligible studies for this question.